Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case

Front Immunol. 2023 Oct 13:14:1276295. doi: 10.3389/fimmu.2023.1276295. eCollection 2023.

Abstract

Central nervous system (CNS) involvement in multiple myeloma (MM) is a rare and challenging complication associated with poor prognosis and limited treatment options. Emerging T-cell directing therapies, such as bispecific antibodies (bsAbs) and chimeric antigen receptor T cells (CAR-T), have shown remarkable success in treating MM, but their efficacy in CNS involvement remains unclear. Elranatamab, a humanized bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3-expressing T cells, has demonstrated promising results in relapsed refractory MM. However, its efficacy in treating CNS-MM has not been reported. We present a case of a 37-year-old male MM patient with CNS involvement who has been successfully treated with Elranatamab.

Keywords: BCMA; CNS involvement; Elranatamab; bispecific Ab; multiple myeloma.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Bispecific* / therapeutic use
  • B-Cell Maturation Antigen
  • Humans
  • Immunotherapy, Adoptive / methods
  • Male
  • Multiple Myeloma* / drug therapy

Substances

  • Antibodies, Bispecific
  • B-Cell Maturation Antigen

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.